专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240180827A1 SUSPENSION CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE 审中-公开
公开(公告)号：US20240180827A1
公开(公告)日：2024-06-06
申请号：US18553141
申请日：2022-03-29
申请人： SENJU PHARMACEUTICAL CO., LTD. , MOCHIDA PHARMACEUTICAL CO., LTD.
发明人： Yuki YAMASHITA
IPC分类号： A61K9/10 , A61K9/00 , A61K31/353 , A61K47/02 , A61K47/10 , A61K47/26 , A61K47/38 , A61K47/44
CPC分类号： A61K9/10 , A61K9/0048 , A61K31/353 , A61K47/02 , A61K47/10 , A61K47/26 , A61K47/38 , A61K47/44
摘要： The present disclosure provides suspendable ophthalmic solutions with excellent redispersibility. The present disclosure provides an aqueous suspension agent comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, a cellulosic polymer, and a nonionic surfactant.

2. 发明申请

US20230102590A1 USE OF POLYETHER COMPOUND 有权
公开(公告)号：US20230102590A1
公开(公告)日：2023-03-30
申请号：US17796843
申请日：2021-02-02
申请人： Senju Pharmaceutical Co., Ltd.
发明人： Noriaki NISHIDA
IPC分类号： A61K31/765 , A61K47/02 , A61K47/18 , A61K9/00
摘要： The present disclosure provides the use of a polyether compound. In one embodiment, the present disclosure relates to improvement of the stability of a polyether compound that uses a polyether compound and improvement of the solubility of a sparingly soluble compound. In one embodiment, the present disclosure relates to a composition that includes a chelating compound, the composition being for stabilizing a polyether compound. In one embodiment, the present disclosure relates to a composition for improving the solubility of a sparingly soluble compound, the composition including at least one of a hydrophobic polyoxyaliphatic moiety-containing polyether compound and a hydrating compound, by combining a hydrophobic polyoxyaliphatic moiety-containing polyether compound and a hydrating compound. In one embodiment, regarding the present disclosure, regarding the polyether compound, the polyether compound includes a poloxamer and polyethylene glycol.

3. 发明申请

US20220296580A1 THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM 有权
公开(公告)号：US20220296580A1
公开(公告)日：2022-09-22
申请号：US17831843
申请日：2022-06-03
申请人： Kyoto Prefectural Public University Corporation , The Doshisha , Senju Pharmaceutical Co., Ltd.
发明人： Noriko KOIZUMI , Naoki OKUMURA , Shigeru KINOSHITA
IPC分类号： A61K31/4439 , A61K9/00 , A61K31/437 , A61K31/444 , C07K16/22 , A61K31/519 , A61K31/713 , A61K38/00 , A61K39/395 , A61K31/4709
摘要： The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.

4. 发明授权

US10660934B2 Neuroprotective peptide 有权
公开(公告)号：US10660934B2
公开(公告)日：2020-05-26
申请号：US16087780
申请日：2017-03-30
申请人： SENJU PHARMACEUTICAL CO., LTD.
发明人： Takeshi Nakajima , Mamiko Machida , Yujiro Hayashi
IPC分类号： C07K7/06 , A61K38/08 , A61K38/00 , A61P27/02 , A61P9/10 , A61P25/28 , A61P21/02 , A61P25/08 , A61P25/16 , C12N15/00 , C12N15/09
摘要： A peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing the peptide, and a preventive or alleviative pharmaceutical composition. The peptide comprises proline-rich protein 4 having the sequence of SEQ ID NO:1 or a partial sequence thereof, or a modified sequence thereof, which has a neuroprotective action.

5. 发明申请

US20190111104A1 NEUROPROTECTIVE PEPTIDE 审中-公开
公开(公告)号：US20190111104A1
公开(公告)日：2019-04-18
申请号：US16087780
申请日：2017-03-30
申请人： SENJU PHARMACEUTICAL CO., LTD.
发明人： Takeshi NAKAJIMA , Mamiko MACHIDA , Yujiro HAYASHI
IPC分类号： A61K38/08 , A61P25/08 , A61P25/16 , A61P25/28 , A61P21/02 , A61P27/02 , A61P9/10 , C07K7/06
摘要： The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This is based on the finding that a peptide fragment isolated from proline-rich protein 4 (PRP4) has a neuroprotective action.

6. 发明申请

US20180105563A1 AGENT FOR PREVENTION OR TREATEMENT OF CORNEAL DISORDERS 审中-公开
公开(公告)号：US20180105563A1
公开(公告)日：2018-04-19
申请号：US15566640
申请日：2016-04-15
申请人： The University of Tokyo , Senju Pharmaceutical Co., Ltd.
发明人： Tomohiko USUI , Chiho YABUTA
IPC分类号： C07K14/47 , A61K38/17 , A61K9/00 , A61P27/02
CPC分类号： C07K14/4705 , A61K9/0048 , A61K38/1709 , A61P27/02
摘要： An object of the invention is to provide an agent for preventing or treating corneal disorders, such as corneal epithelial disorder, dry eye, and reduction in corneal sensitivity. This object is achieved by using angiopoietin-like protein 7 as an active ingredient.

7. 发明授权

US09907750B2 Two-layer separation-type eye drop containing squalane 有权
公开(公告)号：US09907750B2
公开(公告)日：2018-03-06
申请号：US14778359
申请日：2014-03-18
申请人： SENJU PHARMACEUTICAL CO., LTD.
发明人： Shirou Sawa
IPC分类号： A61K9/08 , A61K47/32 , A61K31/01 , A61K31/728 , A61K9/00 , A61K47/26
CPC分类号： A61K9/08 , A61K9/0048 , A61K31/01 , A61K31/728 , A61K47/26 , A61K47/32 , A61K2300/00
摘要： The purpose of the present invention is to provide a technique for formulating a two-layer separation-type ophthalmic solution in which, during storage, an aqueous layer and an oil-containing layer containing squalane are separated from each other, wherein it is possible to homogeneously disperse the oil-containing layer in the aqueous layer while suppressing foaming by shaking the ophthalmic solution before administration, and the homogeneous dispersed state is maintained in a stable manner at least until administration. A two-layer separation-type ophthalmic solution containing squalane and water, wherein hyaluronic acid and/or a salt thereof and polyvinyl alcohol are contained in the ophthalmic solution and the polyvinyl alcohol content is set to 0.025 to 0.1 w/v %, whereby it is possible to homogeneously disperse the oil-containing layer in the aqueous layer while suppressing foaming by shaking the ophthalmic solution before administration, and to maintain the homogeneous dispersed state in a stable manner at least until administration.

8. 发明授权

US09562231B2 Therapeutic agent for corneal epithelial disorder 有权
标题翻译：角膜上皮病的治疗剂
公开(公告)号：US09562231B2
公开(公告)日：2017-02-07
申请号：US14914962
申请日：2014-08-27
申请人： SENJU PHARMACEUTICAL CO., LTD.
发明人： Ayumi Nakagawa , Takeshi Nakajima , Mitsuyoshi Azuma
IPC分类号： C07H21/02 , C07H21/04 , C12N15/11 , A61K48/00 , C12N15/113 , C12N5/079
CPC分类号： C12N15/113 , C12N5/0621 , C12N2310/113 , C12N2310/3231 , C12N2320/30 , C12N2501/65 , C12N2310/321 , C12N2310/3521
摘要： A therapeutic agent for a corneal epithelial disorder, containing a miR-203 inhibitor; an agent for promoting proliferation of corneal epithelial cells, containing a miR-203 inhibitor; a liquid culture medium for use in the manufacture of a corneal epithelial sheet, containing a miR-203 inhibitor; and a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using a liquid culture medium containing a miR-203 inhibitor. According to the present invention, a therapeutic agent for a corneal epithelial disorder, an agent for promoting proliferation of corneal epithelial cells, a liquid culture medium for use in the manufacture of a corneal epithelial sheet, a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using the liquid culture medium, and a method for treating a corneal epithelial disorder can be provided. The present inventors have also found that not only the above effects are exhibited by inhibiting miRNA richly contained in tears, but also the agent specifically acts on eye surfaces, so that the present invention can be expected to show high safety.
摘要翻译：用于角膜上皮病症的治疗剂，其含有miR-203抑制剂; 用于促进角膜上皮细胞增殖的试剂，其含有miR-203抑制剂; 用于制造含有miR-203抑制剂的角膜上皮片的液体培养基; 以及角膜上皮片的制造方法，包括使用含有miR-203抑制剂的液体培养基培养角膜上皮细胞的步骤。根据本发明，用于角膜上皮疾病的治疗剂，角膜上皮细胞增殖剂，用于制造角膜上皮片的液体培养基，角膜上皮片的制造方法，包括可以提供使用液体培养基培养角膜上皮细胞的步骤和治疗角膜上皮病的方法。本发明人还发现，通过抑制泪液中富含的miRNA，不但能够显示上述效果，而且具体地作用在眼表面上，从而可以期待本发明的安全性高。

9. 发明申请

US20160317528A1 COMBINED AGENT FOR CELL THERAPY OF CORNEAL ENDOTHELIAL CELL 审中-公开
标题翻译：组合细胞治疗角膜内皮细胞的药物
公开(公告)号：US20160317528A1
公开(公告)日：2016-11-03
申请号：US15108355
申请日：2013-12-27
申请人： KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION , THE DOSHISHA , SENJU PHARMACEUTICAL CO., LTD.
发明人： Noriko KOIZUMI , Naoki OKUMURA , Shigeru KINOSHITA
IPC分类号： A61K31/4745 , A61K9/00 , A61K35/44 , A61K35/30
CPC分类号： A61K31/4745 , A61K9/0048 , A61K35/30 , A61K35/44 , A61K45/06
摘要： The present invention provides an agent for treating or preventing a disease, a disorder or a condition of a corneal endothelium, said agent comprising a corneal endothelial cell and a myosin II-specific inhibitor. More specifically, the myosin II-specific inhibitor is blebbistatin. The disease, the disorder or the condition is typically a disorder associated with Fuchs endothelial corneal dystrophy or corneal endothelial dysfunction (bullous keratopathy). Also provided is a method for treating or preventing a corneal endothelial disease, said method comprising a step of administering an effective amount of a myosin II-specific inhibitor together with a corneal endothelial cell to a subject.
摘要翻译：本发明提供了用于治疗或预防角膜内皮的疾病，病症或病症的药剂，所述药物包含角膜内皮细胞和肌球蛋白II特异性抑制剂。更具体地说，肌球蛋白II特异性抑制剂是blebbistatin。疾病，病症或病症通常是与Fuchs内皮角膜营养不良或角膜内皮功能障碍（大疱性角膜病）相关的病症。还提供了治疗或预防角膜内皮细胞疾病的方法，所述方法包括向受试者施用有效量的肌球蛋白II特异性抑制剂与角膜内皮细胞一起的步骤。

10. 发明授权

US09144609B2 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid 有权
标题翻译：含有2-氨基-3-（4-溴苯甲酰基）苯乙酸的含水液体制剂
公开(公告)号：US09144609B2
公开(公告)日：2015-09-29
申请号：US14269692
申请日：2014-05-05
申请人： SENJU PHARMACEUTICAL CO., LTD.
发明人： Shirou Sawa , Shuhei Fujita , George A. Baklayan , Angeliqueo E. Padilla
IPC分类号： A01N37/18 , A61K31/165 , A01N37/44 , A61K31/24 , A01N37/10 , A61K31/19 , A61K47/10 , A61K9/00 , A61K31/196 , A61K47/34 , A61K47/32 , A61K47/02 , A61K47/18 , A61K47/14
CPC分类号： A61K47/10 , A61K9/0043 , A61K9/0048 , A61K31/196 , A61K47/02 , A61K47/14 , A61K47/183 , A61K47/186 , A61K47/32 , A61K47/34
摘要： An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. An embodiment of said liquid preparation does not include any preservative. Said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
摘要翻译：含有2-氨基-3-（4-溴苯甲酰基）苯乙酸或其药理学上可接受的盐或其水合物的本发明的含水液体制剂，烷基芳基聚醚醇型聚合物如泰洛沙夫或聚乙二醇脂肪酸酯如聚乙二醇单硬脂酸酯是稳定的。所述液体制剂的一个实施方案不包括任何防腐剂。所述滴眼剂形式的水性液体制剂可用于治疗睑炎，结膜炎，巩膜炎和术后炎症。此外，本发明的鼻滴形式的水性液体制剂可用于治疗过敏性鼻炎和炎症性鼻炎（例如慢性鼻炎，肥大性鼻炎，鼻息肉等）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式